US adults recruited online who reported at least three months of weekly semaglutide or tirzepatide submitted a photograph of their medication for blinded coding. Among 322 participants, self-report and photo coding agreed for 82.6%, with a kappa of 0.78. Photo review classified 25.8% as using compounded products, two thirds of whom had self-reported one of the branded formulations.
Why it is interesting: Two thirds of those coded as compounded users had named a branded product when asked.
Abstract — the authors' own words, CC BY
Objective
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are dominating the type 2 diabetes and obesity intervention landscape, yet their real-world use is increasingly difficult to characterize amid widespread availability of non-FDA-approved, compounded products obtained outside traditional healthcare systems. These users may not be captured by the clinical and claims databases commonly used in real-world GLP-1RA research. Online surveys offer a scalable alternative for reaching this population; however, existing survey studies depend on self-reported medication use, the reliability of which has not been well characterized. Methods
An online study was conducted among U.S. adults recruited via Prolific who reported ≥ 3 months use of once-weekly injectable semaglutide or tirzepatide. Participants completed a screening survey requiring a photo of the prescribed GLP-1RA, followed by a main survey for eligible participants assessing self-reported GLP-1RA type and sociodemographic and health characteristics. Two blinded, independent coders classified photos as one of four FDA-approved branded formulations or a compounded product; discrepancies were resolved by the second author. Agreement was assessed using Cohen's kappa. Results
Of the 419 screening survey participants, 322 participants comprised the analytic sample; 22 of the total exclusions were based on medication photo review. Self-reported and photo-coded medication types showed substantial agreement (82.61%; Cohen's κ = 0.78, 95% CI [0.73, 0.83]). Photo review classified 83 participants (25.78%) as using compounded GLP-1RAs; among these, 54 (65.06%) self-reported using one of the four branded GLP-1RAs and 29 (34.94%) selected a "none of the above" response option, operationalized as compounded use. Conclusions
This study demonstrated that photo review may be a feasible method for improving medication classification in research and offered recommendations for future studies. Additional work is needed to evaluate this protocol in larger and more diverse samples and to refine formulation-specific self-report items.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.